TherapeuticsMD, Inc. (TXMD) EPS Estimated At $-0.22

October 13, 2018 - By Winifred Garcia

TherapeuticsMD, Inc. (NASDAQ:TXMD) LogoInvestors sentiment decreased to 1.24 in Q2 2018. Its down 0.23, from 1.47 in 2018Q1. It turned negative, as 16 investors sold TherapeuticsMD, Inc. shares while 35 reduced holdings. 19 funds opened positions while 44 raised stakes. 156.02 million shares or 2.78% less from 160.49 million shares in 2018Q1 were reported.
State Of Wisconsin Inv Board holds 0% or 171,200 shares. Quantbot L P reported 0.01% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD). Price T Rowe Assocs Inc Md owns 23.40 million shares. Raymond James Na stated it has 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Dupont Capital has invested 0.01% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Parallax Volatility Advisers Lp invested in 0% or 9,098 shares. Oppenheimer Incorporated accumulated 0.01% or 58,834 shares. Northern Tru stated it has 0% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD). Proshare Advsr Lc has 113,162 shares. Ing Groep Nv reported 268,138 shares. Stifel Financial stated it has 1.94 million shares. Axa invested in 1.06M shares. Parametric Portfolio Assocs Lc stated it has 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Zeke Capital Ltd Liability Co owns 10,330 shares. Greenwood Cap Assoc Limited Liability stated it has 0.12% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD).

Since August 21, 2018, it had 1 buying transaction, and 3 insider sales for $3.80 million activity. Milligan John C.K. IV also sold $1.52M worth of TherapeuticsMD, Inc. (NASDAQ:TXMD) on Monday, September 10. $22,100 worth of TherapeuticsMD, Inc. (NASDAQ:TXMD) was bought by Thompson Tommy G. Bernick Brian had sold 182,800 shares worth $1.15 million.

Analysts expect TherapeuticsMD, Inc. (NASDAQ:TXMD) to report $-0.22 EPS on November, 5.They anticipate $0.15 EPS change or 214.29 % from last quarter’s $-0.07 EPS. After having $-0.15 EPS previously, TherapeuticsMD, Inc.’s analysts see 46.67 % EPS growth. The stock decreased 3.04% or $0.17 during the last trading session, reaching $5.42. About 3.15M shares traded or 26.87% up from the average. TherapeuticsMD, Inc. (NASDAQ:TXMD) has declined 1.40% since October 13, 2017 and is downtrending. It has underperformed by 17.02% the S&P500.

TherapeuticsMD, Inc. operates as a women's health care product company. The company has market cap of $1.28 billion. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. It currently has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

TherapeuticsMD, Inc. (NASDAQ:TXMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>